122 318

Cited 0 times in

Effects of Cannabidiol on Adaptive Behavior and Quality of Life in Pediatric Patients With Treatment-Resistant Epilepsy

DC Field Value Language
dc.contributor.author강훈철-
dc.contributor.author구청모-
dc.contributor.author김세희-
dc.contributor.author이준수-
dc.contributor.author김흥동-
dc.contributor.author주봉림-
dc.date.accessioned2022-12-22T04:09:25Z-
dc.date.available2022-12-22T04:09:25Z-
dc.date.issued2022-09-
dc.identifier.issn1738-6586-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/192056-
dc.description.abstractBackground and purpose: Data regarding the effects of cannabidiol (CBD) on the quality of life (QOL) are currently inadequate. We assessed the QOL of pediatric patients with epilepsy who were treated with CBD. Methods: This prospective, open-label study included pediatric and adolescent patients (aged 2-18 years) with Dravet syndrome or Lennox-Gastaut syndrome. Oral CBD was administered at 10 mg/kg/day. The Korean version of the Quality Of Life in Childhood Epilepsy (QOLCE) questionnaire was administered when CBD treatment began and again after 6 months. Adaptive behavior was measured using the Korean versions of the Child Behavior Checklist (K-CBCL) and the second edition of the Vineland Adaptive Behavior Scales (Vineland-II). Results: This study included 41 patients (11 with Dravet syndrome and 30 with Lennox-Gastaut syndrome), of which 25 were male. The median age was 4.1 years. After 6 months, 26.8% (11/41) of patients experienced a ≥50% reduction in the number of seizures. The total score for the QOLCE questionnaire did not change from baseline to after 6 months of CBD treatment (85.71±39.65 vs. 83.12±48.01, respectively; p=0.630). The score in the motor skills domain of Vineland-II reduced from 48.67±13.43 at baseline to 45.18±14.08 after 6 months of treatment (p=0.005). No other Vineland-II scores and no K-CBCL scores had changed after 6 months of CBD treatment. Conclusions: CBD is an efficacious antiseizure drug used to treat Dravet syndrome and Lennox-Gastaut syndrome. However, it did not improve the patient QOL in our study, possibly because all of our patients had profound intellectual disabilities.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.languageEnglish-
dc.publisherKorean Neurological Association-
dc.relation.isPartOfJOURNAL OF CLINICAL NEUROLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleEffects of Cannabidiol on Adaptive Behavior and Quality of Life in Pediatric Patients With Treatment-Resistant Epilepsy-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Pediatrics (소아과학교실)-
dc.contributor.googleauthorSe Hee Kim-
dc.contributor.googleauthorHan Som Choi-
dc.contributor.googleauthorChung Mo Koo-
dc.contributor.googleauthorBong-Rim Joo-
dc.contributor.googleauthorByung-Joo Park-
dc.contributor.googleauthorHae Kook Lee-
dc.contributor.googleauthorJoon Soo Lee-
dc.contributor.googleauthorHeung Dong Kim-
dc.contributor.googleauthorHoon-Chul Kang-
dc.identifier.doi10.3988/jcn.2022.18.5.547-
dc.contributor.localIdA00102-
dc.contributor.localIdA06014-
dc.contributor.localIdA00611-
dc.contributor.localIdA03177-
dc.contributor.localIdA01208-
dc.relation.journalcodeJ01327-
dc.identifier.eissn2005-5013-
dc.identifier.pmid36062772-
dc.subject.keywordLennox-Gastaut syndrome-
dc.subject.keywordSCN1A-
dc.subject.keywordadaptive-
dc.subject.keyworddrug-resistant epilepsy-
dc.contributor.alternativeNameKang, Hoon Chul-
dc.contributor.affiliatedAuthor강훈철-
dc.contributor.affiliatedAuthor구청모-
dc.contributor.affiliatedAuthor김세희-
dc.contributor.affiliatedAuthor이준수-
dc.contributor.affiliatedAuthor김흥동-
dc.citation.volume18-
dc.citation.number5-
dc.citation.startPage547-
dc.citation.endPage552-
dc.identifier.bibliographicCitationJOURNAL OF CLINICAL NEUROLOGY, Vol.18(5) : 547-552, 2022-09-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.